Update (July 27): The US Justice Department will investigate whether Cassava Sciences manipulated results pertaining to its experimental Alzheimer’s drug, sources tell Reuters, though neither the government nor the biotech has confirmed the launch of the investigation.
Five studies coauthored by Hoau-Yan Wang at the City University of New York and colleagues were pulled from PLOS ONE over concerns about data integrity yesterday (March 30), Retraction Watch reports. Wang, who already had another retraction to his name and who contributed to three other papers that have received expressions of concern, conducted research on an Alzheimer’s therapy called Simufilam that is under development by Austin, Texas–based Cassava Sciences (formerly Pain Therapeutics). Wang is also a paid advisor to the company, and Cassava employee Lindsay Burns is a coauthor on two of the newly retracted papers, which don’t pertain to Simufilam or Alzheimer’s disease.
Citing “people familiar with the matter,” The Wall ...
